Amphastar P Market Cap ($980.07 Million)
Market Cap & Net Worth: Amphastar P (AMPH)
Amphastar P market cap. Amphastar P (NASDAQ:AMPH) has a market capitalization of $980.07 Million ($980.07 Million) as of November 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #8705 globally and #2523 in its home market, demonstrating a 9.58% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Amphastar P's stock price $28.02 by its total outstanding shares 42537944 (42.54 Million). Also see Amphastar P (AMPH) cash flow conversion for how efficiently the company converts equity into cash flow.
Amphastar P Market Cap History (2015–2026)
Amphastar P market cap history from 2015 to 2026. Data shows growth from $605.31 Million to $1.19 Billion (7.80% CAGR). Check AMPH stock price for real-time trading data and today's change.
Index Memberships
Amphastar P is a constituent of 4 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.04% | #251 of 976 |
|
NASDAQ Composite
IXIC
|
$40.12 Trillion | 0.00% | #943 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.84 Trillion | 0.05% | #143 of 263 |
|
S&P Small-Cap 600 Index
SML
|
$1.55 Trillion | 0.08% | #466 of 602 |
Weight: Amphastar P's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Amphastar P Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Amphastar P's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Amphastar P net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
1.58x
Amphastar P's market cap is 1.58 times its annual revenue
Latest Price to Earnings (P/E) Ratio
11.61x
Amphastar P's market cap is 11.61 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $783.55 Million | $255.16 Million | $10.53 Million | 3.07x | 74.40x |
| 2017 | $818.43 Million | $240.18 Million | $4.51 Million | 3.41x | 181.55x |
| 2018 | $846.51 Million | $294.67 Million | -$5.74 Million | 2.87x | N/A |
| 2019 | $820.56 Million | $322.36 Million | $48.94 Million | 2.55x | 16.77x |
| 2020 | $855.44 Million | $349.85 Million | $1.40 Million | 2.45x | 609.72x |
| 2021 | $990.71 Million | $437.77 Million | $62.12 Million | 2.26x | 15.95x |
| 2022 | $1.19 Billion | $498.99 Million | $91.39 Million | 2.39x | 13.04x |
| 2023 | $2.63 Billion | $644.39 Million | $137.54 Million | 4.08x | 19.13x |
| 2024 | $1.58 Billion | $731.97 Million | $159.52 Million | 2.16x | 9.90x |
| 2025 | $1.14 Billion | $719.89 Million | $98.09 Million | 1.58x | 11.61x |
Competitor Companies of AMPH by Market Capitalization
Companies near Amphastar P in the global market cap rankings as of November 5, 2026. Also see Amphastar P asset portfolio for a full breakdown of the balance sheet.
Key companies related to Amphastar P by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #514 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #538 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #588 globally with a market cap of $45.79 Billion USD ( CN¥312.89 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #621 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #514 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #538 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $47.80 |
| #588 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.79 Billion | CN¥49.05 |
| #621 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.50 |
Market Capitalization of Amphastar P (2015–2026)
Market capitalization of Amphastar P from 2015 to today. Between 2015 and today, Amphastar P's market cap moved from $605.31 Million to $ 1.19 Billion, with a yearly change of 7.80%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.19 Billion | +4.63% |
| 2025 | $1.14 Billion | -27.88% |
| 2024 | $1.58 Billion | -39.97% |
| 2023 | $2.63 Billion | +120.74% |
| 2022 | $1.19 Billion | +20.31% |
| 2021 | $990.71 Million | +15.81% |
| 2020 | $855.44 Million | +4.25% |
| 2019 | $820.56 Million | -3.07% |
| 2018 | $846.51 Million | +3.43% |
| 2017 | $818.43 Million | +4.45% |
| 2016 | $783.55 Million | +29.44% |
| 2015 | $605.31 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Amphastar P was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $980.07 Million USD |
| MoneyControl | $980.07 Million USD |
| MarketWatch | $980.07 Million USD |
| marketcap.company | $980.07 Million USD |
| Reuters | $980.07 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Amphastar P
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mi… Read more